Addex Therapeutics’ Phase II Epilepsy Drug in Partnership with J&J Fails to Meet Endpoints

1. Addex Therapeutics, in partnership with Johnson & Johnson (J&J), has announced that its lead drug candidate for epilepsy failed to meet clinical endpoints in a Phase II study.
2. The drug candidate, developed for the treatment of epilepsy, did not demonstrate the desired efficacy in the Phase II clinical trial, leading to disappointment for both Addex and J&J.
3. Addex Therapeutics and J&J are currently evaluating the future development of the drug candidate, considering the results of the Phase II study.
4. The failure of the Phase II trial highlights the challenges and risks involved in drug development, particularly in the field of neurological disorders such as epilepsy.
5. Despite the setback, Addex Therapeutics remains committed to advancing its pipeline of drug candidates for various neurological and psychiatric disorders.
6. The partnership between Addex and J&J, established in 2013, aimed to develop novel treatments for epilepsy and other neurological conditions. The recent failure of the Phase II trial may prompt a reevaluation of the partnership's strategy and focus.